Eton Pharmaceuticals (ETON) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Immunome (IMNM) over the past year, gaining 269.7% versus a loss of 15.3%. Over five years, ETON leads with a +1341.9% price change compared with -7.5% for IMNM. Immunome is the larger company by market cap ($1.85 billion vs $1.76 billion), about 1.1 times the size, while Eton Pharmaceuticals is growing revenue faster (+104.9% vs -23.2%).
Eton Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.8% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | IMNM |
|---|---|---|
| Share price | $60.85 | $15.69 |
| Market cap | $1.76B | $1.85B |
| 1-day change | -0.83% | -5.54% |
| YTD return | +259.85% | -26.96% |
| 1-year return | +269.68% | -15.33% |
| 5-year return | +1341.94% | -7.54% |
| P/E ratio (TTM) | 39.51 | — |
| Forward P/E | 18.41 | — |
| EPS (TTM) | $1.54 | $-2.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $79.95M | $6.94M |
| Revenue growth (YoY) | +104.94% | -23.23% |
| Net income (latest FY) | $-4.60M | $-212.39M |
| Gross margin | 53.46% | — |
| Operating margin | -1.06% | -3228.83% |
| Net margin | -5.75% | -3059.99% |
| 52-week high | $70.64 | $30.06 |
| 52-week low | $14.27 | $15.55 |
| Distance from 52-week high | -13.86% | -47.80% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +32.70% | +123.90% |
| Average volume | 570.79K | 1.36M |
| Shares outstanding | 28.84M | 118.07M |
| Employees | 44 | 267 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed IMNM by 285.0 percentage points over the past year.
- Eton Pharmaceuticals is more profitable, keeping -5.8 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs -23.23%).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 267 employees
ETON vs IMNM FAQ
Which is bigger, Eton Pharmaceuticals or Immunome?
Immunome (IMNM) is larger, with a market capitalization of $1.85B compared with $1.76B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ETON or IMNM?
ETON returned +269.68% over the past 12 months, compared with -15.33% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Immunome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.